Business Description
Citi Pharma Ltd
ISIN : PK0126201018
Share Class Description:
KAR:CPHL: Ordinary SharesCompare
Compare
Traded in other countries / regions
CPHL.Pakistan IPO Date
2021-07-09Description
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.6 | |||||
9-Day RSI | 26.54 | |||||
14-Day RSI | 34.43 | |||||
3-1 Month Momentum % | 2.08 | |||||
6-1 Month Momentum % | -1.4 | |||||
12-1 Month Momentum % | -0.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.68 | |||||
Forward Dividend Yield % | 4.68 | |||||
5-Year Yield-on-Cost % | 4.62 |
Profitability Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
EV-to-Forward-Revenue | 0.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Citi Pharma Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₨) | |||
| EPS (TTM) (₨) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 1.05 | ||
| 3-Year Sortino Ratio | 2.67 | ||
| Volatility % | 26.33 | ||
| 14-Day RSI | 34.43 | ||
| 14-Day ATR (₨) | 2.042302 | ||
| 20-Day SMA (₨) | 79.103 | ||
| 12-1 Month Momentum % | -0.17 | ||
| 52-Week Range (₨) | 69.25 - 104.25 | ||
| Shares Outstanding (Mil) | 228.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Citi Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Citi Pharma Ltd Stock Events
| Event | Date | Price (₨) | ||
|---|---|---|---|---|
| PKR 3.500000 Cash Dividend | 2025-10-17 | 92.97 (+1.05%) | ||
| PKR 3.250000 Cash Dividend | 2024-10-17 | 44.44 (-0.11%) | ||
| 1.1:1 Stock Split | 2021-10-18 | 39.37 (+1.19%) |
Show
Entries
Citi Pharma Ltd Frequently Asked Questions
What is Citi Pharma Ltd(KAR:CPHL)'s stock price today?
The current price of KAR:CPHL is ₨75.08. The 52 week high of KAR:CPHL is ₨104.25 and 52 week low is ₨69.25.
When is next earnings date of Citi Pharma Ltd(KAR:CPHL)?
The next earnings date of Citi Pharma Ltd(KAR:CPHL) is .
Does Citi Pharma Ltd(KAR:CPHL) pay dividends? If so, how much?
The Dividend Yield %  of Citi Pharma Ltd(KAR:CPHL) is 4.68% (As of Today), Highest Dividend Payout Ratio of Citi Pharma Ltd(KAR:CPHL) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Citi Pharma Ltd(KAR:CPHL) is 4.68%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Citi Pharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers